Envoy Medical (COCH) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Envoy Medical is expected to report Q3 2026 results before market open on November 5. Analysts forecast a loss of $0.70 per share and revenue of approximately $0.09 million; a conference call is scheduled for November 10.
• The company’s previous quarter exceeded expectations, reporting a $0.70-per-share loss versus the $0.80 consensus estimate, while revenue matched forecasts at $0.05 million.
• Analyst sentiment is mixed: two firms rate the stock Buy, one rates it Hold and one Sell, producing an average Hold rating and a $21.67 price target. Shares recently traded at $6.66, up 2.3%.

Envoy Medical (NASDAQ:COCH - Get Free Report) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Envoy Medical to post earnings of ($0.70) per share and revenue of $0.09 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 9:30 AM ET.

Envoy Medical (NASDAQ:COCH - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.70) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.10. The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.05 million. On average, analysts expect Envoy Medical to post ($3.10) EPS for the current fiscal year and ($1.80) EPS for the next fiscal year.

Envoy Medical Stock Up 2.3%

Shares of COCH stock opened at $6.66 on Thursday. The stock has a 50-day simple moving average of $6.90 and a 200 day simple moving average of $6.87. The stock has a market capitalization of $514.09 million, a P/E ratio of -0.88 and a beta of 1.97. Envoy Medical has a fifty-two week low of $3.63 and a fifty-two week high of $9.54.

Wall Street Analysts Forecast Growth

COCH has been the subject of a number of research analyst reports. Weiss Ratings reissued a "sell (e+)" rating on shares of Envoy Medical in a report on Monday, October 19th. Lake Street Capital lifted their price objective on shares of Envoy Medical from $2.50 to $25.00 and gave the stock a "buy" rating in a research note on Tuesday. HC Wainwright reiterated a "buy" rating on shares of Envoy Medical in a report on Tuesday, October 13th. Finally, Loop Capital set a $20.00 target price on shares of Envoy Medical in a research note on Monday, July 27th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Envoy Medical presently has an average rating of "Hold" and an average price target of $21.67.

About Envoy Medical

Envoy Medical is a medical technology company focused on developing fully implanted hearing devices for people with sensorineural hearing loss. Unlike conventional hearing aids and many cochlear implants, its technology is designed to be placed beneath the skin, with no external wearable sound processor.

The company's lead product is the Acclaim Cochlear Implant, a fully implanted cochlear implant intended to address moderate-to-profound sensorineural hearing loss in adults. The system is designed to use the body's natural anatomy to capture sound and convert it into electrical signals that stimulate the auditory nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.